The overall objectives of the University of Virginia (UVA) Cancer Center's Office of Clinical Research (OCR) are to provide a central clinical research infrastructure to: ? Facilitate the activation and administration of research clinical studies ? Assist Cancer Center Principal Investigators and clinicians in the screening and enrolling of patients on clinical research studies ? Monitor compliance with all regulatory aspects of clinical trials in conjunction with the Protocol Review Committee, IRB, state, and federal guidelines ? Provide a training and education program for all Cancer Center staff involved in clinical research studies ? Provide support for internal and external quality assurance audits ? Communicate the availability of clinical research studies to Cancer Center physicians, referring physicians, and the community ? Recommend, develop, implement, and maintain state-of-the-art information systems to support the workflow, data sharing, analyses, and reporting requirements of cancer clinical research studies ? Train users on the Forte Research Systems, OnCore? clinical research management system

Public Health Relevance

Rigorous clinical research that meets the highest scientific and regulatory standards requires a robust infrastructure to support the opening and management of clinical trials. That is the mission of the OCR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-21
Application #
8231148
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-02-01
Project End
2017-01-31
Budget Start
2012-06-05
Budget End
2013-01-31
Support Year
21
Fiscal Year
2012
Total Cost
$258,904
Indirect Cost
$94,694
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Heuslein, Joshua L; Murrell, Kelsey P; Leiphart, Ryan J et al. (2016) Vascular growth responses to chronic arterial occlusion are unaffected by myeloid specific focal adhesion kinase (FAK) deletion. Sci Rep 6:27029
Ma, Zhenjun; Kim, Youngchul; Hu, Feifang et al. (2016) Point success rate for patient therapeutic response prediction by continuous biomarker scores. Stat Methods Med Res 25:1638-47
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother 65:1201-12
Pelkofski, Elizabeth; Stine, Jessica; Wages, Nolan A et al. (2016) Cervical Cancer in Women Aged 35 Years and Younger. Clin Ther 38:459-66
Showalter, Timothy N; Camacho, Fabian; Cantrell, Leigh A et al. (2016) Determinants of Quality Care and Mortality for Patients With Locally Advanced Cervical Cancer in Virginia. Medicine (Baltimore) 95:e2913
Mauldin, Ileana S; Wages, Nolan A; Stowman, Anne M et al. (2016) Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunol Immunother 65:1189-99
Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859
Kolpaczynska, Milena; DeRosa, Christopher A; Morris, William A et al. (2016) Thienyl Difluoroboron β-Diketonates in Solution and Polylactide Media. Aust J Chem 69:537-545
Sloane, Hillary S; Landers, James P; Kelly, Kimberly A (2016) Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. J Mol Diagn 18:546-53
Cheng, Bei; He, Huacheng; Huang, Tao et al. (2016) Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. J Biomed Nanotechnol 12:435-49

Showing the most recent 10 out of 413 publications